These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5822623)

  • 61. FURTHER OBSERVATIONS OF THE BINDING AND INHIBITION OF DIHYDROFOLIC REDUCTASE BY FOLIC ACID ANTAGONISTS.
    SCHRECKER AW; HUENNEKENS FM
    Biochem Pharmacol; 1964 May; 13():731-42. PubMed ID: 14181276
    [No Abstract]   [Full Text] [Related]  

  • 62. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
    Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
    Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
    Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
    Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
    Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate.
    Browman GP; Gorka C; Mehta C; Lazarus H; Abelson HT
    Biochem Pharmacol; 1980 Aug; 29(16):2241-5. PubMed ID: 7426028
    [No Abstract]   [Full Text] [Related]  

  • 68. Irreversible enzyme inhibitors. CXXIX. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. V. Effects of substitution on the benzenesulfonyl fluoride moiety on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jul; 11(4):677-82. PubMed ID: 5244346
    [No Abstract]   [Full Text] [Related]  

  • 69. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
    Zhao R; Babani S; Gao F; Liu L; Goldman ID
    Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Triazines and related products. Part XV. 2,4-Diaminopyrimidines and 2-aminopyrimidin-4(3H)-ones bearing 1,2,3-benzotriazinyl groups as potential dihydrofolic reductase inhibitors.
    Brown TB; Stevens MF
    J Chem Soc Perkin 1; 1975; (11):1023-8. PubMed ID: 1170192
    [No Abstract]   [Full Text] [Related]  

  • 71. Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
    Gangjee A; Shi J; Queener SF
    J Med Chem; 1997 Jun; 40(12):1930-6. PubMed ID: 9191971
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inactivation by mouse serum of a tightly bound inhibitor of dihydrofolate reductase.
    Fölsch E; Bertino JR
    Mol Pharmacol; 1970 Jan; 6(1):93-8. PubMed ID: 5535872
    [No Abstract]   [Full Text] [Related]  

  • 73. Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
    Gangjee A; Zeng Y; McGuire JJ; Mehraein F; Kisliuk RL
    J Med Chem; 2004 Dec; 47(27):6893-901. PubMed ID: 15615538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design and synthesis of histidine analogues of folic acid and methotrexate as potential folylpolyglutamate synthetase inhibitors.
    Mao Z; Pan J; Kalman TI
    J Med Chem; 1996 Oct; 39(21):4340-4. PubMed ID: 8863812
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Formulation of de novo substituent constants in correlation analysis: inhibition of dihydrofolate reductase by 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted pyrimidines.
    Hansch C; Silipo C; Steller EE
    J Pharm Sci; 1975 Jul; 64(7):1186-91. PubMed ID: 1151681
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A comparison of the inhibition of bovine and murine leukemia dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-X-phenyl)-s-triazines.
    Guo ZR; Dietrich SW; Hansch C; Dolnick BJ; Bertino JR
    Mol Pharmacol; 1981 Nov; 20(3):649-56. PubMed ID: 7329407
    [No Abstract]   [Full Text] [Related]  

  • 77. Pyrimido(4,5-c)isoquinolines. 2. Synthesis and biological evaluation of some 6-alkyl-,6-aralkyl-, and 6-aryl-1,3-diamino-7,8,9,10-tetrahydropyrimido(4,5-c)isoquinolines as potential folate antagnoists 1.
    Rosowsky A; Papathanasopoulos N
    J Med Chem; 1974 Dec; 17(12):1272-6. PubMed ID: 4214925
    [No Abstract]   [Full Text] [Related]  

  • 78. Potential folic acid antagonists. 6. Potential irreversible folate reductase inhibitors derived from 2,4-diamino-5-arylazopyrimidines.
    Chatterjee SS; Moran JF; Triggle DJ; Wayne A
    J Med Chem; 1971 Dec; 14(12):1244-5. PubMed ID: 5116249
    [No Abstract]   [Full Text] [Related]  

  • 79. Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).
    Barlow HC; Bowman KJ; Curtin NJ; Calvert AH; Golding BT; Huang B; Loughlin PJ; Newell DR; Smith PG; Griffin RJ
    Bioorg Med Chem Lett; 2000 Mar; 10(6):585-9. PubMed ID: 10741559
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Irreversible enzyme inhibitors. CLXXIV. Metabolism of 4-(p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)hydrocinnamido)-o-toluenesulfonyl fluoride (NSC-113423), an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Ryan AJ; Vermeulen NM; Baker BR
    J Med Chem; 1970 Nov; 13(6):1140-2. PubMed ID: 5479853
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.